ReviewExpert review of respiratory medicine2022
DNA methylation in pulmonary fibrosis and lung cancer.
Review in Expert review of respiratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Diagnostic performance of SHOX2 and RASSF1A gene methylation assays in malignant pleural effusion: A systematic review and meta-analysis.Cancer cytopathology · 2025Pooled it
- Advances and frontiers in pulmonary fibrosis and lung cancer research (2000-2024): a bibliometric analysis.Frontiers in medicine · 2025Pooled it
- Feedback loops between DNMT1 and autophagy as well as senescence promotes organ aging and canities.Autophagy · 2026Article
- Epigenetic Modulation of Thyroid-Stimulating Hormone Receptor Expression in Orbital Fibroblasts From Graves' Ophthalmopathy: Target for Treatment.Investigative ophthalmology & visual science · 2026Article
- Epigenetic mechanisms and steroid-resistant nephrotic syndrome: The future potential for SRNS diagnosis.iScience · 2026Review
- DNMT3b promotes proliferation and invasion by mediating HOPX DNA methylation in lung cancer.iScience · 2026Article
- From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration.Human mutation · 2026Review
- DNA methylation features and diagnostic model establishment of MET amplification in lung adenocarcinoma.Therapeutic advances in medical oncology · 2026Article
- The Role of DNA Methylation in Osteosarcoma Pathogenesis and Therapy.OncoTargets and therapy · 2026Review
- KAT2A: a prognostic biomarker influencing proliferation and immune escape in lung adenocarcinoma.BMC cancer · 2025Article
- Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis.Respiratory research · 2025Review
- Genome-wide DNA methylation analysis of Astragalus on the intervention of ID2 promoter via PI3K/Akt signaling pathway in peritoneal fibrosis.Scientific reports · 2025Article
- Scoring Pulmonary Fibrosis Following COVID-19 Pneumonia with Quantitative HRCT: Relationship with Clinical Parameters, Mean Platelet Volume and Lymphocyte/Monocyte RatioThoracic research and practice · 2025Article
- Review
- Expressions of shox2, RASSF1A and PTGER4, and the relationship between their methylation and clinicopathological characteristics in patients with lung cancer.Journal of medical biochemistry · 2025Article
- Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.MedComm · 2025Review
- Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer.Medical oncology (Northwood, London, England) · 2025Review
- The role of epigenetics in pulmonary fibrosis: recent advances in mechanistic insights and therapeutic implications.Frontiers in molecular biosciences · 2025Review
- Article
- Serum biomarker changes in pulmonary fibrosis with lung cancer and their correlation with patient survival prognosis.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionPulmonary fibrosis is an age-related, progressive, and fatal disease with a median survival of 3-5 years after diagnosis; idiopathic pulmonary fibrosis (IPF) is the most common type. It is characterized by fibroblast proliferation and accumulation of excessive extracellular matrix. Patients with IPF are at increased risk for lung cancer. Epigenetic mechanisms are involved in lung fibrosis and cancer, and DNA methylation is critical in disease pathogenesis and progression. Therefore, studies of DNA methylation contribute to better understanding of the underlying mechanisms of these two respiratory diseases, and can offer novel diagnostic and treatment options. AREAS COVERED: This review discusses the latest advances in our understanding of epigenetic factors related to DNA methylation that impact development of lung cancer and pulmonary fibrosis, discusses the role of DNA methylation in promoting or inhibiting these diseases, and proposes its potential clinical significance in disease diagnosis and treatment. EXPERT OPINION: DNA methylation plays a critical role in lung cancer and fibrosis pathogenesis. DNA methylation offers a new biomarker for disease diagnosis or monitoring, and provides a new therapeutic target for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.